Unique Avenue of Ventrus Biosciences (VTUS) a Topic of PharmalotArticle
Prize-winning journalist and founder of the popular biotechnology website www.pharmalot.com, Ed Silverman authored an article today on Ventrus Biosciences (NASDAQ: VTUS) titled, “A Little Company Tackles A Big Pain In The Butt.” While the title was catchy and done in a bit of light manner, Mr. Silverman did a great job in capturing the relevance of what Ventrus is striving to achieve with their lead drug, Inferanserin (VEN 309), a new chemical entity for the topical treatment of hemorrhoids. The drug targets a specific serotonin receptor (5HT2A) believed to be important in the control of the often-times painful ailment. While…